
    
      Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop
      Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will
      directly seek mutations that could identify subjects at risk.
    
  